Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study.

Conclusions: Our preliminary data show that umPEA administered for three month reduces pain intensity and the number of attacks per month in pediatric patients with migraine. Although the small number of patients and the lack of control group do not allow us to consider these initial results as definitely reliable, they encourage us to expand the sample. PMID: 32377286 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32377286?dopt=Abstract

Source: Pain Research and Management - May 8, 2020 Category: Anesthesiology Authors: Papetti L, Sforza G, Tullo G, Alaimo di Loro P, Moavero R, Ursitti F, Ferilli MAN, Tarantino S, Vigevano F, Valeriani M Tags: Pain Res Manag Source Type: research